Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5698558	CHATTEM SANOFI	Methods for treating allergic disorders using optically pure (-) cetirizine	Jul, 2013 (10 years ago)
US5698558 (Pediatric)	CHATTEM SANOFI	Methods for treating allergic disorders using optically pure (-) cetirizine	Jan, 2014 (10 years ago)

Xyzal is owned by Chattem Sanofi.

Xyzal contains Levocetirizine Dihydrochloride.

Xyzal has a total of 2 drug patents out of which 2 drug patents have expired.

Expired drug patents of Xyzal are:

Xyzal was authorised for market use on 28 January, 2008.

Xyzal is available in tablet;oral, solution;oral dosage forms.

Xyzal can be used as relief of symptoms associated with seasonal and perennial allergic rhinitis.

The generics of Xyzal are possible to be released after 26 January, 2014.

Drug Exclusivity	Drug Exclusivity Expiration
Pediatric Exclusivity(PED)	Feb 21, 2013
New Patient Population(NPP)	Aug 21, 2012

Market Authorisation Date: 28 January, 2008

Treatment: Relief of symptoms associated with seasonal and perennial allergic rhinitis

Dosage: SOLUTION;ORAL; TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.5 mg/mL	14 Jan, 2009	1	07 Nov, 2011	24 Sep, 2012	Eligible
5 mg	17 Dec, 2007	1	26 Nov, 2010	24 Sep, 2012	Eligible

Strength	Dosage	Availability
2.5MG/5ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SOLUTION;ORAL	Discontinued
5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued

Xyzal patents expiration